JP2023527358A5 - - Google Patents

Info

Publication number
JP2023527358A5
JP2023527358A5 JP2022572568A JP2022572568A JP2023527358A5 JP 2023527358 A5 JP2023527358 A5 JP 2023527358A5 JP 2022572568 A JP2022572568 A JP 2022572568A JP 2022572568 A JP2022572568 A JP 2022572568A JP 2023527358 A5 JP2023527358 A5 JP 2023527358A5
Authority
JP
Japan
Prior art keywords
pulmonary fibrosis
pharmaceutical composition
salt
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022572568A
Other languages
English (en)
Japanese (ja)
Other versions
JP7745571B2 (ja
JP2023527358A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2021/050457 external-priority patent/WO2021237273A1/en
Publication of JP2023527358A publication Critical patent/JP2023527358A/ja
Publication of JP2023527358A5 publication Critical patent/JP2023527358A5/ja
Application granted granted Critical
Publication of JP7745571B2 publication Critical patent/JP7745571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022572568A 2020-05-28 2021-05-17 肺線維症を処置する方法 Active JP7745571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901743 2020-05-28
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (3)

Publication Number Publication Date
JP2023527358A JP2023527358A (ja) 2023-06-28
JP2023527358A5 true JP2023527358A5 (https=) 2024-05-14
JP7745571B2 JP7745571B2 (ja) 2025-09-29

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572568A Active JP7745571B2 (ja) 2020-05-28 2021-05-17 肺線維症を処置する方法

Country Status (9)

Country Link
US (1) US20230190746A1 (https=)
EP (1) EP4157278A4 (https=)
JP (1) JP7745571B2 (https=)
KR (1) KR20230017843A (https=)
CN (1) CN115867281A (https=)
AU (1) AU2021279205B2 (https=)
CA (1) CA3177652A1 (https=)
NZ (1) NZ793855A (https=)
WO (1) WO2021237273A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3001119T3 (es) 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) * 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
ES3001119T3 (es) * 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK

Similar Documents

Publication Publication Date Title
JP2024540183A5 (https=)
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
JP2023002662A5 (https=)
JP2010532373A5 (https=)
JP2010532372A5 (https=)
JP2015528471A5 (https=)
JP2017531038A5 (https=)
JP2020507589A5 (https=)
JP2015508749A5 (https=)
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
JP2008521827A5 (https=)
JP2023527358A5 (https=)
PH12021552930A1 (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
JP2020512337A5 (https=)
JP2019517587A5 (https=)
JP2014513123A5 (https=)
JP2021152008A5 (https=)
CN115803328A (zh) 哌嗪-2,3-二酮衍生物及其在医药上的应用
JP2016514141A5 (https=)
JP2010527985A5 (https=)
JP2019533660A5 (https=)
JPWO2023195530A5 (https=)
JP2024544538A5 (https=)
JP2022551691A5 (https=)
JP2009511450A5 (https=)